While Biocryst Pharmaceuticals Inc has overperformed by 2.16%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, BCRX rose by 13.43%, with highs and lows ranging from $11.31 to $6.01, whereas the simple moving average jumped by 1.21% in the last 200 days.
On April 29, 2025, Cantor Fitzgerald started tracking Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) recommending Overweight. A report published by Wedbush on February 25, 2025, Initiated its previous ‘Outperform’ rating for BCRX. JP Morgan also rated BCRX shares as ‘Overweight’, setting a target price of $10 on the company’s shares in an initiating report dated November 20, 2023. RBC Capital Mkts September 18, 2023d the rating to Outperform on September 18, 2023, and set its price target from $9 to $10. Jefferies August 04, 2023d its ‘Hold’ rating to ‘Buy’ for BCRX, as published in its report on August 04, 2023. BofA Securities’s report from July 13, 2023 suggests a price prediction of $10 for BCRX shares, giving the stock a ‘Buy’ rating. Needham also rated the stock as ‘Buy’.
Analysis of Biocryst Pharmaceuticals Inc (BCRX)
Further, the quarter-over-quarter increase in sales is 49.41%, showing a positive trend in the upcoming months.
There are several well-rounded types of analysis and research techniques that can be used to gain a clear view of Biocryst Pharmaceuticals Inc’s future performance, with equity being one of the most critical indicators. Taking into account the quick ratio of the company, currently set at 2.22, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
As an indicator of volatility for any stock, average volume can also be very valuable, and BCRX is recording an average volume of 3.77M. On a monthly basis, the volatility of the stock is set at 3.59%, whereas on a weekly basis, it is put at 2.84%, with a loss of -0.81% over the past seven days. Furthermore, long-term investors anticipate a median target price of $17.10, showing growth from the present price of $8.53, which can serve as yet another indication of whether BCRX is worth investing in or should be passed over.
How Do You Analyze Biocryst Pharmaceuticals Inc Shares?
Apart from looking at the fundamentals, you should also pay attention to the number of company employees who own shares. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 3.68%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 83.89% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
